News Release

Pre-existing mutations can lead to drug resistance in HIV virus

In a critical step that may lead to more effective HIV treatments, Harvard scientists have found pre-existing mutations in a small number of HIV patients

Peer-Reviewed Publication

PLOS

In a critical step that may lead to more effective HIV treatments, Harvard scientists have found pre-existing mutations in a small number of HIV patients. These mutations can cause the virus to develop resistance to the drugs used to slow its progression.

The finding is particularly important because, while researchers have long known HIV can develop resistance to some drugs, it was not understood whether the virus relied on pre-existing mutations to develop resistance, or if it waits for those mutations to occur. By shedding new light on how resistance evolves, the study, reported in online journal PLoS Computational Biology opens the door to the development of new, more effective treatments.

Pennings collected her data from 26 clinical trials. Patients were treated with a typical combination of NNRTI drugs, which helps block the virus from multiplying. She found that the virus is more likely to develop resistance shortly after the start of treatment or when treatment is restarted following an interruption of a week or more. However, it is less likely to develop resistance later on and when patients do not interrupt treatment.

"In order to prevent the evolution of resistance, we need to know where the resistance mutations are coming from, it was exciting to realize data from clinical trials could help us solve this puzzle," Pennings said. "If we understand how the virus develops resistance, we can think of new ways to prevent it."

This finding suggests that pre-existing mutations are behind the virus' drug resistance, and that resistance which develops early in treatment is likely the result of pre-existing mutations. Resistance that develops later is tied to mutations in the virus that occur after treatment began.

While the study holds out hope for the future development of more effective HIV treatments, Pennings emphasized that data used in the study came from trials, which exclusively included patients receiving NNRTI or unboosted protease inhibitor treatments. It is unclear whether the results can be generalized to other treatments and to patients who are not enrolled in clinical trials.

###

FINANCIAL DISCLOSURE: This work was supported by a long-term fellowship of the Human Frontier Science Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

COMPETING INTERESTS: The authors have declared that no competing interests exist.

CITATION: Pennings PS (2012) Standing Genetic Variation and the Evolution of Drug Resistance in HIV. PLoS Comput Biol 8(6): e1002527. doi:10.1371/journal.pcbi.1002527

PLEASE ADD THIS LINK TO THE FREELY AVAILABLE ARTICLE IN ONLINE VERSIONS OF YOUR REPORT (the link will go live when the embargo ends): http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1002527

CONTACT:
Dr. Pleuni Pennings
Harvard University
Organismic and Evolutionary Biology
16 Divinity Avenue
Cambridge, Massachussets 02138
UNITED STATES
617 417 7311
http://scholar.harvard.edu/pennings/home

Disclaimer

This press release refers to an upcoming article in PLoS Computational Biology. The release is provided by journal staff, or by the article authors and/or their institutions. Any opinions expressed in this release or article are the personal views of the journal staff and/or article contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

Media Permissions

PLoS Journals publish under a Creative Commons Attribution License, which permits free reuse of all materials published with the article, so long as the work is cited (e.g., Brinkworth RSA, O'Carroll DC (2009) Robust Models for Optic Flow Coding in Natural Scenes Inspired by Insect Biology. PLoS Comput Biol 5(11): e1000555. doi:10.1371/journal.pcbi.1000555). No prior permission is required from the authors or publisher. For queries about the license, please contact the relative journal contact indicated here: http://www.plos.org/about/media-inquiries/embargo-policy/

About PLoS Computational Biology

PLoS Computational Biology features works of exceptional significance that further our understanding of living systems at all scales through the application of computational methods. All works published in PLoS Computational Biology are open access. Everything is immediately available subject only to the condition that the original authorship and source are properly attributed. Copyright is retained.

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.